From Yahoo Finance: 2025-05-27 09:55:00

Loomis Sayles released its Q1 2025 investor letter for the Global Growth Fund, with a -3.35% return compared to -1.32% for the MSCI ACWI Net Index. Positive impacts from stock selection in consumer staples, communication services, and healthcare sectors were noted along with allocations to information technology and healthcare sectors.

Novartis AG (NYSE:NVS) was highlighted in Loomis Sayles Global Growth Fund’s Q1 2025 letter. Novartis is a pharmaceutical company with a 0.11% one-month return and a 12.16% gain over the last 52 weeks. On May 23, 2025, Novartis AG (NYSE:NVS) stock closed at $112.75 per share with a market cap of $227.204 billion.

Novartis AG (NYSE:NVS) is a diversified global healthcare company with market leadership in various treatment areas. The company generates revenue from branded pharmaceuticals worldwide, with a significant focus on innovative medicines. Revenue is primarily derived from the Americas, Europe, and the rest of the world.

Novartis AG (NYSE:NVS) was not among the 30 most popular stocks among hedge funds in Q1 2025. While the company has potential as an investment, hedge funds see greater promise in AI stocks for higher returns within a shorter timeframe. Novartis AG (NYSE:NVS) was also covered in an article about undervalued stocks.

For more investor letters from hedge funds and other leading investors, visit the hedge fund investor letters Q1 2025 page. Additional articles on stock trends and market insights are available for further reading. Disclosure: None.

Read more: What Makes Novartis AG (NVS) a Differentiated Business?